|Bionomics||BNC105||Oncology||Vascular Disruption Agent|
|Brane Discovery||BND-11624||CNS - neuropathic pain||Novel pyrrolidinone derivative. Target undisclosed but same class as nefiracetam and levetiracetam, the latter of which targets synaptic vesicle protein SV2A|
|MedImmune||CAM-3001||Rheumatoid arthritis||Human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR)|
|Santen Pharmaceutical||DE-102||macular edema||Steroidal treatment using Oakwood's Chroniject sustained release delivery technology.|
|University of Pennsylvania & University of Florida||undisclosed||Blindness (hereditary) - Leber congenital amaurosis type 2 (LCA2)||RPE65 gene therapy|
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.